J Korean Diabetes.
2013 Sep;14(3):138-142. 10.4093/jkd.2013.14.3.138.
Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis
- Affiliations
-
- 1Department of Internal Medicine, School of Medicine, Kangwon National University, Chuncheon, Korea. ehcho@kangwon.ac.kr
- KMID: 2173923
- DOI: http://doi.org/10.4093/jkd.2013.14.3.138
Abstract
- Recently, dipeptidylpeptidase-4 (DPP-4) inhibitors have been widely used as a second-line therapy for type 2 diabetes because of their glucose-lowering efficacy, weight neutral effects and minimal hypoglycemia. However, there have been concerns regarding the lack of evidence of the long-term consequences of DPP-4 inhibitors on cardiovascular disease, acute pancreatitis and cancers; therefore, the effects of DPP-4 inhibitors on these three major diseases are reviewed in this article. A growing body of evidence demonstrates the cardioprotective role of DPP-4 inhibitors in animal and small clinical studies. However, clearly conflicting data regarding the effects of DPP-4 inhibitors on cancers and pancreatitis have been presented in preclinical and epidemiologic studies. The forthcoming long-term clinical studies on cardiovascular safety will provide more conclusive answers relating to the safety of DPP-4 inhibitors, including their effects on cancer and pancreatitis.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008–2016
- DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes
- Dipeptidyl Peptidase-4 Inhibitor
- Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice
- Comparison of DPP-4 Inhibitors
